As a chief player in the worldwide biotechnological industry, AMGen Inc. is both a developer and producer of innovative pharmaceutical drugs based on gene editing technique. The Amgen pharmaceuticals have proven in praxis their effectiveness against serious human diseases. The Amgen R&D establishments reside in many US and European cities. Clinical research studies on the cellular and molecular levels are carried out by over 17 000 highly competent company's research associates. The organization is an establisher of the Amgen Foundation, whose goal is a promotion of academic education and training of skilled workers medical personnel. In 15 years of its work, the fund has invested over $ 200 million in the development of the medical academic community. The fund has also supported various states in rectification of the consequences of large-scale fatal casualties and at various times participated in charity events and implementations of worthy causes.
Nyní budete vždy vědět, do kterých akcií je výhodnější investovat